{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:55:51Z","timestamp":1778867751006,"version":"3.51.4"},"reference-count":17,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0081","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:01Z","timestamp":1752836041000},"source":"Crossref","is-referenced-by-count":4,"title":["The probability of remaining under active surveillance for localized prostate cancer: An analysis of young patients in the framework of the multicenter ProjuMa registry study"],"prefix":"10.3238","author":[{"given":"Kevin","family":"Claassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Justenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Brandhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jale","family":"Lakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiltraud","family":"Kaj\u00fcter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Karpinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Stang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"10.3238\/arztebl.m2025.0081_ref1","unstructured":"Robert Koch-Institut: Krebs in Deutschland f\u00fcr 2019\/2020. Robert Koch-Institut 2023. www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_node.html (last accessed on 13 May 2025)."},{"key":"10.3238\/arztebl.m2025.0081_ref2","doi-asserted-by":"crossref","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415\u201324","DOI":"10.1056\/NEJMoa1606220"},{"key":"10.3238\/arztebl.m2025.0081_ref3","doi-asserted-by":"crossref","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.: Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023; 388: 1547\u201358","DOI":"10.1016\/j.eururo.2023.08.014"},{"key":"10.3238\/arztebl.m2025.0081_ref4","doi-asserted-by":"crossref","unstructured":"Timilshina N, Alibhai SMH, Tomlinson G, Sander B, Cheung DC, Finelli A: Long-term outcomes following active surveillance of low-grade prostate cancer: A population-based study using a landmark approach. J Urol 2023; 209: 540\u20138","DOI":"10.1097\/JU.0000000000003097"},{"key":"10.3238\/arztebl.m2025.0081_ref5","doi-asserted-by":"crossref","unstructured":"Mottet N, Bellmunt J, Bolla M, et al.: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618\u201329","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"10.3238\/arztebl.m2025.0081_ref6","unstructured":"Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF: S3-Leitlinie Prostatakarzinom: Langversion 6.2 2021. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Prostatatkarzinom\/Version_6\/LL_Prostatakarzinom_Langversion_6.2.pdf (last accessed on 13 May 2025)"},{"key":"10.3238\/arztebl.m2025.0081_ref7","doi-asserted-by":"crossref","unstructured":"Shee K, Cowan JE, Balakrishnan A, et al.: Limited relevance of the very low risk prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort. Eur Urol 2023; 84: 9\u201312","DOI":"10.1016\/j.eururo.2023.02.013"},{"key":"10.3238\/arztebl.m2025.0081_ref8","doi-asserted-by":"crossref","unstructured":"Chandrasekar T, Bowler N, Schneider A, et al.: Outcomes of active surveillance for men with intermediate risk prostate cancer: A population-based analysis. Urology 2021; 155: 101\u20139","DOI":"10.1016\/j.urology.2021.05.068"},{"key":"10.3238\/arztebl.m2025.0081_ref9","doi-asserted-by":"crossref","unstructured":"Remmers S, Helleman J, Nieboer D, et al.: Active surveillance for men younger than 60 years or with intermediate-risk localized prostate cancer. Descriptive analyses of clinical practice in the movember GAP3 initiative. Eur Urol Open Sci 2022; 41: 126\u201333","DOI":"10.1016\/j.euros.2022.05.012"},{"key":"10.3238\/arztebl.m2025.0081_ref10","doi-asserted-by":"crossref","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al.: Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425\u201337","DOI":"10.1056\/NEJMoa1606221"},{"key":"10.3238\/arztebl.m2025.0081_ref11","doi-asserted-by":"crossref","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al.: Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evidence 2023; 2: EVIDoa2300018","DOI":"10.1056\/EVIDx2300122"},{"key":"10.3238\/arztebl.m2025.0081_ref12","doi-asserted-by":"crossref","unstructured":"Salari K, Kuppermann D, Preston MA, et al.: Active surveillance of prostate cancer is a viable option for men younger than 60 years. J Urol 2019; 201: 721\u20137","DOI":"10.1097\/JU.0000000000000031"},{"key":"10.3238\/arztebl.m2025.0081_ref13","unstructured":"Greenwood M: The natural duration of cancer. Rep Public Health Med Subj 1926; 33: 1\u201326."},{"key":"10.3238\/arztebl.m2025.0081_ref14","doi-asserted-by":"crossref","unstructured":"Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV: Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Netw Open 2023; 6: e231439","DOI":"10.1001\/jamanetworkopen.2023.1439"},{"key":"10.3238\/arztebl.m2025.0081_ref15","doi-asserted-by":"crossref","unstructured":"Timilshina N, Komisarenko M, Martin LJ, et al.: Factors associated with discontinuation of active surveillance among men with low-risk prostate cancer: A population-based study. J Urol 2021; 206: 903\u201313","DOI":"10.1097\/JU.0000000000001903"},{"key":"10.3238\/arztebl.m2025.0081_ref16","unstructured":"Deutsche Krebsgesellschaft: Jahresbericht der zertifizierten Prostatakrebszentren: Kennzahlenauswertung 2023. Deutsche Krebsgesellschaft: Berlin 2023."},{"key":"10.3238\/arztebl.m2025.0081_ref17","doi-asserted-by":"crossref","unstructured":"van Hemelrijck M, Ji X, Helleman J, et al.: Reasons for discontinuing active surveillance: Assessment of 21 centres in 12 countries in the movember GAP3 consortium. Eur Urol 2019; 75: 523\u201331","DOI":"10.1016\/j.eururo.2018.10.025"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:10Z","timestamp":1752836050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":17,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0081","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}